Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sonnet BioTherapeutics Holdings ( (SONN) ) has provided an announcement.
Sonnet BioTherapeutics announced promising preclinical data for its lead drug candidate, SON-1010, an albumin-binding IL-12 fusion protein, aimed at improving cancer treatment efficacy. By enhancing cytokine half-life and tumor targeting, SON-1010 shows potential in combating solid tumors, including ovarian cancer, with ongoing Phase 1/2a clinical trials in collaboration with Roche. This breakthrough could revolutionize cancer immunotherapy, offering a new hope for treatment-resistant cancers.
For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.
